Hyperoxaluria, Primary (Type I)
Synonyms of Hyperoxaluria, Primary (Type I)
- PH Type I
- No subdivisions found.
Primary Hyperoxaluria (Type I) is a hereditary disorder characterized by an inborn error of glyoxylate. Excessive formation of oxalate occurs in the liver, resulting in excessive levels of oxalate in the blood and urine. Calcium oxalate does not dissolve and consequently stones are formed in the urinary tract.
Symptoms of Primary Hyperoxaluria (Type I) may begin at any time throughout life, and can occur during infancy, but usually begin between 2 and 10 years of age. The symptoms may include intense abdominal pain radiating to the groin, blood that can be seen in the urine, and the passage of kidney stones. Oxalosis refers to the deposition of calcium oxalate in body tissues, and symptoms may vary, depending upon where this happens.
Primary Hyperoxaluria (Type I) is a hereditary disorder transmitted in an autosomal recessive fashion. An inborn error of glyoxylate metabolism causes an excess of oxalate in the urine, leading to formation of calcium oxalate stones in the kidney. Human traits including the classic genetic diseases, are the product of the interaction of two genes for that condition, one received from the father and one from the mother. In recessive disorders, the condition does not appear unless a person inherits the same defective gene for the same trait from each parent. If an individual receives one normal gene and one gene for the disease, the person will be a carrier for the disease, but usually will not show symptoms. The risk of transmitting the disease to the children of a couple, both of whom are carriers for a recessive disorder, is 25 percent. Fifty percent of their children risk being carriers of the disease, but generally will not show symptoms of the disorder. Twenty-five percent of their children may receive both normal genes, one from each parent, and will be genetically normal (for that particular trait). The risk is the same for each pregnancy.
Primary Hyperoxaluria (Type I) affects males and females in equal numbers. It is a rare disorder.
A minority of patients with Primary Hyperoxaluria (Type I) may be helped by large doses of pyridoxine (vitamin B6). Orthophosphate, magnesium or citrate therapies may reduce the risk of stone formation. Plenty of liquid should be consumed to dilute the urine, thus minimizing the risk of formation of calcium oxalate stones. Small kidney stones may be passed in the urine spontaneously. Others may be broken up by shock wave fragmentation (lithotrypsy), although large stones may require surgery. If kidney function deteriorates beyond a certain level, hemodialysis and/or kidney transplantation may be considered. Liver transplantation is curative for Primary Hyperoxaluria (Type I).
Genetic counseling may be helpful to families of Primary Hyperoxaluria (Type I) patients.
Studies are underway to use oxalate-degrading intestinal bacteria to reduce the body burden of oxalate in patients with Primary Hyperoxaluria (Type I).
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
Organizations related to Hyperoxaluria, Primary (Type I)
Gagnadoux MD et al. Long term results of liver-kidney transplantation in children with primary hyperoxaluria. Pediatr Nephrol. 2001;16:946-50.
Monico CG, Milliner DS. Combined liver-kidney and kidney-alone transplantation in primary hyperoxaluria. Liver Transpl. 2001;7:954-63.
Marangella M et al. The primary hyperoxalurias. Contrib Nephrol. 2001;136:11-32.
Amorosa A et al. AGXT gene mutations and their influence on clinical heterogeneity of type I primary hyperoxaluria. J Am Soc Nephrol. 2001;12:1072-79.
Langman CB. The optimal approach to the patient with oxalosis. Adv Ren Replace Ther. 2001;8:214-22.
Leumann E, Hoppe B. The primary hyperoxalurias. J Am Soc Nephrol. 2001;12:1986-93.
Ellis SR, et al. Combined lvier-kidney transplantation for primary hyperoxaluria type I in young children. Nephrol Dial Transplant. 2001;16:348-54.
Rumsby G. Biochemical and genetic diagnosis of the primary hyperoxalurias: a review. Mol Urol. 2000;4:349-54.
Milliner DS, Wilson DM, Smith LH. Phenotypic expression of primary hyperoxaluria: comparative features of types I and II. Kidney Int. 2001;59:31-36.
Lumb MJ, Danpure CJ. Functional synergism between the most common polymorphism in human alanine:glyoxylate saminotransferase and four fo the most common disease-causing mutations. J Biol Chem. 2000;275:36415-22.
Cochat P, Basmaison O. Current approaches to the management of primary hyperoxaluria. Arch Dis Child. 2000;82:470-73.
FROM THE INTERNET
McKusick VA, ed. Online Mendelian Inheritance in Man (OMIM). Baltimore. MD: The Johns Hopkins University; Entry No: 259900;Last Update:11/5/2002.
The information in NORD’s Rare Disease Database is for educational purposes only. It should never be used for diagnostic or treatment purposes. If you have questions regarding a medical condition, always seek the advice of your physician or other qualified health professional. NORD’s reports provide a brief overview of rare diseases. For more specific information, we encourage you to contact your personal physician or the agencies listed as “Resources” on this report.
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.
Copyright ©1987, 1988, 1989, 1995, 2002, 2007
Report last updated: 2007/08/08 00:00:00 GMT+0
NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.